Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × SCLC × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 28 Carcinoma, Hepatocellular 18 Small Cell Lung Carcinoma 14 Sarcoma 12 Carcinoma, Non-Small-Cell Lung 12 Ovarian Neoplasms 11 Colorectal Neoplasms 11 Breast Neoplasms 10 Nasopharyngeal Carcinoma 9 Esophageal Squamous Cell Carcinoma 9 Triple Negative Breast Neoplasms 8 Cholangiocarcinoma 8 Squamous Cell Carcinoma of Head and Neck 6 Head and Neck Neoplasms 5 Esophageal Neoplasms 5 Biliary Tract Neoplasms 5 Melanoma 4 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Thyroid Neoplasms 3 Solid Tumor 3 Recurrence 3 Pancreatic Neoplasms 3 Osteosarcoma 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Glioma 3 Carcinoma, Adenoid Cystic 3 Neoplasms 2 Nasopharyngeal Neoplasms 2

Interventions

apatinib 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡